Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gilead Sciences Inc. | Lenacapavir - (CALIBRATE) | HIV | Phase 2 | Trial Completed | Subcutaneous | Anti-HIV |
| Gilead Sciences Inc. | Magrolimab with Azacitidine | Myelodyspastic syndrome and acute myeloid leukemia (AML) | Phase 2 | Trial Discontinued | Intravenous | Hematology |
| Gilead Sciences Inc. | Magrolimab in Combination With Rituximab | Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Trial Completed | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Relapsed/Refractory Multiple Myeloma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Head and neck squamous cell carcinoma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab - (ENHANCE) | Higher risk-Myelodysplastic Syndrome (MDS) | Phase 3 | Trial Discontinued | Intravenous | Hematology |
| Gilead Sciences Inc. | Sacituzumab Govitecan + Pembrolizumab - (EVOKE-02) | Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Relapsed/Refractory Multiple Myeloma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
